Skills Friendly, cheerful, open to ideas of others, aspires to lead and develop colleag ues talents, and desires

to be a productive and supportive member of a team. Proposed grant for PhD project. First author on several publications (see below ). Software: Word, Excel, Outlook, PowerPoint, NCBI, Expasy, SciFinder, SigmaPlot, EndNote, Chimera, ChemDraw, and Canvas. Molecular biology: PCR, cloning, expression, purification of target proteins fr om bacteria, yeast, insect, mammalian cells, as well as animal tissues. Biochemistry: Liquid handling automation, binding and enzymatic fluorescence, f luorescence quench, FRET, FP, ELISA, HPLC, absorbance, and radioassays. Protein characterization: SDS-PAGE, Western Blot, SEC, FPLC, MALDI MS, protein aggregation and solubilization. Education PhD in Biomedical Science (2011) from Ohio State University (Columbus, OH) MBA (2002) from Purdue University (West Lafayette, IN) MS (2001) in Biochemistry from Purdue University (West Lafayette, IN) BS (1997) in Chemistry (Cum Laude) from Utah State University (Logan, UT) Research Associate (2006-Present) at Ohio State University (Columbus, OH): Improved methods for in vitro amyloid peptide and protein aggregation, resulting in improved sensitivity of end-point ThT fluorescence binding assay. Championed adoption of high-throughput technology for academic laboratory. Discovered that BTAs and oxindoles selectively bind to tau fibrils, and develope d patent for imaging agents for early and specific diagnosis of Alzheimers disea se. Identified polarizability as important for compound binding to amyloid fibrils a nd provided evidence that compounds bind to tau fibrils in multiple modes. Senior Associate Scientist (2002-2006) at Pfizer, Inc. (La Jolla, CA): Developed high-throughput, continuous spectrophotometric and end-point fluoresce nce polarization assays for PKC activity. Evaluated PKC inhibitors from HTS group and type II diabetes project chemists. Kinetically characterized target construct proteins from project team molecular biologists to produce data for publication. Supervised undergraduate student interns while teaching them laboratory skills. Research Assistant (1997-2001) at Purdue University (West Lafayette, IN): Synthesized inhibitors of IGPS enzyme and used them in a continuous spectrophoto metric assay to determine substrate binding order.

Teaching Assistant (1997-2002) at Purdue University (West Lafayette, IN): Assembled departmental instrumentation laboratory and served as trainer. Taught chemistry laboratory and accelerated first-year Spanish course. Publications Cisek, K., Jensen, J., Funk, K., Darby, M., and Kuret, J. Oxindole compounds as potential tau-selective imaging agents [In Preparation] Jensen, J., Cisek, K., Darby, M., and Kuret, J. Benzothiazole-aryl compounds as potential tau-selective imaging agents [In Preparation] Kuret, J., Jensen, J., and Cisek, K. Development of tau-selective imaging agents , US Patent [In Preparation] Jensen, J., Cisek, K., Honson, N., and Kuret, J. Compound polarizability fosters potent binding to tau fibrils [In Preparation]. Jensen, J., Cisek, K., Funk, K., Naphade, S., Schafer, K., and Kuret, J. (2011) Research towards tau imaging, J Alzheimers Dis [In Press]. Li, H., Hong, Y., Nukui, S., Lou, J., Johnson, S., Scales, S., Botrous, I., Tomp kins, E., Yin, C., Zhou, R., He, M., Jensen, J., Bouzida, D., Alton, G., Lafonta ine, J., and Grant, S. (2011) Identification of novel pyrrolopyrazoles as protei n kinase C beta II inhibitors, Bioorg Med Chem Lett 21, 584-587. Kim, S., Jensen, J., Cisek, K., Funk, K., Naphade, S., Schafer, K., and Kuret, J . (2010) Imaging as a strategy for premortem diagnosis and staging of tauopathie s, Curr Alzheimer Res 7, 230-234. Grant, S., Tran, P., Zhang, Q., Zou, A., Dinh, D., Jensen, J., Zhou, S., Kang, X ., Zachwieja, J., Lippincott, J., Liu, K., Johnson, S. L., Scales, S., Yin, C., Nukui, S., Stoner, C., Prasanna, G., Lafontaine, J., Wells, P., and Li, H. (2010 ) Discovery of a novel class of targeted kinase inhibitors that blocks protein k inase C signaling and ameliorates retinal vascular leakage in a diabetic rat mod el, Eur J Pharmacol 627, 16-25. Honson, N., Jensen, J., Abraha, A., Hall, G., and Kuret, J. (2009) Small-molecul e mediated neuroprotection in an in situ model of tauopathy, Neurotox Res 15, 27 4-283. Chang, E., Honson, N., Bandyopadhyay, B., Funk, K., Jensen, J., Kim, S., Naphade , S., and Kuret, J. (2009) Modulation and detection of tau aggregation with smal l-molecule ligands, Curr Alzheimer Res 6, 409-414. Honson, N., Jensen, J., Darby, M., and Kuret, J. (2007) Potent inhibition of tau fibrillization with a multivalent ligand, Biochem Biophys Res Commun 363, 229-2 34. Grodsky, N., Li, Y., Bouzida, D., Love, R., Jensen, J., Nodes, B., Nonomiya, J., and Grant, S. (2006) Structure of the catalytic domain of human protein kinase C beta II complexed with a bisindolylmaleimide inhibitor, Biochemistry 45, 13970 -13981. Myers, R., Jensen, J., Deras, I., Smith, J., and Davisson, V. (2003) Substrate-i nduced changes in the ammonia channel for imidazole glycerol phosphate synthase, Biochemistry 42, 7013-7022.

Awards Pfizer, La Jolla Structural Biology and Biochemistry Team Award (2005) Pfizer, La Jolla Recognition Award (2004) Army Achievement Medal (1996)